Tumor necrosis factor inhibitors for rheumatoid arthritis
DL Scott, GH Kingsley - New England Journal of Medicine, 2006 - Mass Medical Soc
DL Scott, GH Kingsley
New England Journal of Medicine, 2006•Mass Medical SocRheumatoid arthritis that was resistant to methotrexate and sulfasalazine developed in a 25-
year-old woman who was evaluated for possible treatment with a tumor necrosis factor
inhibitor. These agents are effective in some patients who have not had a response to other
therapies. They increase the risk of infection, and their long-term efficacy and safety are not
established.
year-old woman who was evaluated for possible treatment with a tumor necrosis factor
inhibitor. These agents are effective in some patients who have not had a response to other
therapies. They increase the risk of infection, and their long-term efficacy and safety are not
established.
Rheumatoid arthritis that was resistant to methotrexate and sulfasalazine developed in a 25-year-old woman who was evaluated for possible treatment with a tumor necrosis factor inhibitor. These agents are effective in some patients who have not had a response to other therapies. They increase the risk of infection, and their long-term efficacy and safety are not established.
The New England Journal Of Medicine